RENB Renovaro: רווח למניה לשנה מתגלגלת

This daily price chart for Renovaro Inc. (RENB) demonstrates an EPS (TTM) of , while the business operates within a protected US legal environment free from geopolitical threats. The company's model relies on the full outsourcing of production and testing, which eliminates plant-related expenditures. However, high volatility and uncertainty regarding clinical outcomes create significant risks for investors.
RENB (Renovaro Biosciences): פילוחים אנליטיים ודוחות לפי אינדיקטורים

By outsourcing molecule synthesis and testing to third-party CRO partners, Renovaro Inc. minimizes capital expenditures, focusing instead on patent ownership. This strategy is reflected in the calculation of the rolling year net income per share growth rate, which allows the net income per share YoY ttm growth rate chart to assess expense management efficiency and business scalability.